Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 6/2021

Open Access 01-06-2021 | Carcinoid Tumor | Neuroendocrine Neoplasms (NS Reed, Section Editor)

Update on Histological Reporting Changes in Neuroendocrine Neoplasms

Authors: Konstantin Bräutigam, Antonio Rodriguez-Calero, Corina Kim-Fuchs, Attila Kollár, Roman Trepp, Ilaria Marinoni, Aurel Perren

Published in: Current Oncology Reports | Issue 6/2021

Login to get access

Abstract

Purpose of Review

Classification and nomenclature of neuroendocrine neoplasms (NEN) have frequently changed over the last years. These changes reflect both increasing knowledge and international standardisation.

Recent Findings

The most recent changes in the Gastro-Entero-Pancreatic system induced the concept of well-differentiated NET with high proliferation rate (NET G3), explaining partially the heterogeneity of G3 NEN. Even if the nomenclature in pulmonary NEN is still different, the terms ‘carcinoid’ and ‘atypical carcinoid’ are widely overlapping with NET G1 and NET G2. Molecular data shows an additional heterogeneity both in well-differentiated NET and poorly differentiated NEC. However, no studies are available demonstrating clinical usefulness yet.

Summary

The heterogeneity of NEN regarding the organ of origin, differentiation and molecular subtypes make development of personalised therapy a challenge needing more international and interdisciplinary collaborations and clinical trials allowing stratification according to biological subgroups.
Literature
1.
Mehrvarz Sarshekeh A, Advani S, Halperin DM, Conrad C, Shen C, Yao JC, et al. Regional lymph node involvement and outcomes in appendiceal neuroendocrine tumors: a SEER database analysis. Oncotarget. 2017;8(59):99541–51.PubMedPubMedCentralCrossRef
2.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.PubMedCrossRef
3.
Oberndorfer S. Karzinoide Tumoren des Dünndarms. Frankf Z Pathol. 1907;1:426–32.
4.••
. Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018;31(12):1770–86 This article represents the latest consensus and updates on nomenclature of Neuroendocrine Neoplasia.PubMedPubMedCentralCrossRef
5.
Banz Y, Berezowska S, de Leval L, Rubbia-Brandt L, Tolnay M, Moch H, et al. Advancing synoptic cancer reports beyond English: the University of Bern/PathoLink approach. Virchows Arch. 2018;473(5):655–6.PubMedCrossRef
6.
7.
Costes V, Marty-Ane C, Picot MC, Serre I, Pujol JL, Mary H, et al. Typical and atypical bronchopulmonary carcinoid tumors: a clinicopathologic and KI-67-labeling study. Hum Pathol. 1995;26(7):740–5.PubMedCrossRef
8.
Pelosi G, Bresaola E, Bogina G, Pasini F, Rodella S, Castelli P, et al. Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol. 1996;27(11):1124–34.PubMedCrossRef
9.
Sobin LHGM, Wittekind C. UICC: TNM classification of malignant tumours. 7th ed. Oxford: Wiley-Blackwell; 2009.
10.
Sorbye H, Baudin E, Borbath I, Caplin M, Chen J, Cwikla JB, et al. Unmet needs in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Neuroendocrinology. 2019;108(1):54–62.PubMedCrossRef
11.
Nagtegaal ID, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology, 2020;76(2):182–188.
12.
Travis W, Burke AP, Marx A, Nicholson AG. WHO classification of tumours of the lung, pleura, thymus and heart. Travis WDBE, Burke AP, Marx A, Nicholson AG. 4 ed. WHO Classification of Tumours. Vol. 7. 2015, Lyon: IARC Press.
13.
Plöckinger U, Wiedenmann B, de Herder WW. ENETS Consensus Guidelines for the Standard of Care in Neuroendocrine Tumors. Neuroendocrinology. 2009;90(2):159–61.PubMedCrossRef
14.
Marinoni I, Kurrer AS, Vassella E, Dettmer M, Rudolph T, Banz V, et al. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology. 2014;146(2):453–60 e5.PubMedCrossRef
15.
Graham RP, Shrestha B, Caron BL, Smyrk TC, Grogg KL, Lloyd RV, et al. Islet-1 is a sensitive but not entirely specific marker for pancreatic neuroendocrine neoplasms and their metastases. Am J Surg Pathol. 2013;37(3):399–405.PubMedCrossRef
16.
Couvelard A, O'Toole D, Turley H, Leek R, Sauvanet A, Degott C, et al. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer. 2005;92(1):94–101.PubMedCrossRef
17.
Schmitt AM, Anlauf M, Rousson V, Schmid S, Kofler A, Riniker F, et al. WHO 2004 Criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors. Am J Surg Pathol. 2007;31(11):1677–82.PubMedCrossRef
18.
Di Domenico A, Pipinikas CP, Maire RS, Bräutigam K, Simillion C, Dettmer MS, et al. Epigenetic landscape of pancreatic neuroendocrine tumours reveals distinct cells of origin andmeans of tumour progression. Commun Biol, 2020;(1):740–43.
19.
Bajetta E, Ferrari L, Martinetti A, Celio L, Procopio G, Artale S, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer. 1999;86(5):858–65.PubMedCrossRef
20.
Cavalcanti MS, Gönen M, Klimstra DS. The ENETS/WHO grading system for neuroendocrine neoplasms of the gastroenteropancreatic system: a review of the current state, limitations and proposals for modifications. Int J Endocr Oncol. 2016;3(3):203–19.PubMedPubMedCentralCrossRef
21.
Chan DL, Clarke SJ, Diakos CI, Roach PJ, Bailey DL, Singh S, et al. Prognostic and predictive biomarkers in neuroendocrine tumours. Crit Rev Oncol Hematol. 2017;113:268–82.PubMedCrossRef
22.
Reid MD, Bagci P, Ohike N, Saka B, Erbarut Seven I, Dursun N, et al. Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies. Mod Pathol. 2015;28(5):686–94.PubMedCrossRef
23.
Oberg K, Modlin IM, De Herder W, Pavel M, Klimstra D, Frilling A, et al. Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol. 2015;16(9):e435–e46.PubMedPubMedCentralCrossRef
24.
Sansone A, Lauretta R, Vottari S, Chiefari A, Barnabei A, Romanelli F, et al. Specific and non- specific biomarkers in neuroendocrine gastroenteropancreatic tumors. Cancers. 2019;11(8):1113.PubMedCentralCrossRef
25.
Modlin IM, Oberg K, Taylor A, Drozdov I, Bodei L, Kidd M. Neuroendocrine tumor biomarkers: current status and perspectives. Neuroendocrinology. 2014;100(4):265–77.PubMedCrossRef
26.
Schmitt AM, Riniker F, Anlauf M, Schmid S, Soltermann A, Moch H, et al. Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases. Am J Surg Pathol. 2008;32(3):420–5.PubMedCrossRef
27.
Nielsen K, Binderup T, Langer SW, Kjaer A, Knigge P, Grøndahl V, et al. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms. BMC Cancer. 2020;20(1):27.PubMedPubMedCentralCrossRef
28.
Konukiewitz B, Schlitter AM, Jesinghaus M, Pfister D, Steiger K, Segler A, et al. Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20. Mod Pathol. 2017;30(4):587–98.PubMedCrossRef
29.
Pinato DJ, Tan TM, Toussi STK, Ramachandran R, Martin N, Meeran K, et al. An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes. Br J Cancer. 2014;110(1):115–22.PubMedCrossRef
30.
Mak IYF, Hayes AR, Khoo B, Grossman A. Peptide receptor radionuclide therapy as a novel treatment for metastatic and invasive phaeochromocytoma and paraganglioma. Neuroendocrinology. 2019;109(4):287–98.PubMedCrossRef
31.
Severi S, Grassi I, Nicolini S, Sansovini M, Bongiovanni A, Paganelli G. Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life. Onco Targets Ther. 2017;10:551–7.PubMedPubMedCentralCrossRef
32.
Ali AS, Grönberg M, Federspiel B, Scoazec J-Y, Hjortland GO, Grønbæk H, et al. Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma. PLoS One. 2017;12(11):e0187667.PubMedPubMedCentralCrossRef
33.
34.
Yachida S, Vakiani E, White CM, Zhong Y, Saunders T, Morgan R, et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol. 2012;36(2):173–84.PubMedPubMedCentralCrossRef
35.•
. Di Domenico A, Wiedmer T, Marinoni I, Perren A. Genetic and epigenetic drivers of neuroendocrine tumours (NET). Endocr Relat Cancer. 2017;24(9):R315–r34 This review summarizes important and state-of-the art knowledge on epigenetic mechanisms of neuroendocrine tumours, a relevant and emerging field.PubMedCrossRef
36.
Chou A, Itchins M, de Reuver PR, Arena J, Clarkson A, Sheen A, et al. ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumors. Hum Pathol. 2018;82:249–57.PubMedCrossRef
37.
Basturk O, Yang Z, Tang LH, Hruban RH, Adsay V, McCall CM, et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol. 2015;39(5):683–90.PubMedPubMedCentralCrossRef
38.
Cavalcanti E, Armentano R, Valentini AM, Chieppa M, Caruso ML. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading. Cell Death Dis. 2017;8(8):e3004.PubMedPubMedCentralCrossRef
39.
Cai L, Michelakos T, Deshpande V, Arora KS, Yamada T, Ting DT, et al. Role of tumor-associated macrophages in the clinical course of pancreatic neuroendocrine tumors (PanNETs). Clin Cancer Res. 2019;25(8):2644–55.PubMedPubMedCentralCrossRef
40.
Bodei L, Sundin A, Kidd M, Prasad V, Modlin IM. The status of neuroendocrine tumor imaging: from darkness to light? Neuroendocrinology. 2015;101(1):1–17.PubMedCrossRef
41.
Bodei L, Schöder H, Baum RP, Herrmann K, Strosberg J, Caplin M, et al. Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy. Lancet Oncol. 2020;21(9):e431–e43.PubMedCrossRefPubMedCentral
42.
43.
44.
Haydu LE, Holt PE, Karim RZ, Madronio CM, Thompson JF, Armstrong BK, et al. Quality of histopathological reporting on melanoma and influence of use of a synoptic template. Histopathology. 2010;56(6):768–74.PubMedCrossRef
45.
Karpathakis A, Dibra H, Thirlwell C. Neuroendocrine tumours: cracking the epigenetic code. Endocr Relat Cancer. 2013;20(3):R65.PubMedCrossRef
46.
Pipinikas CP, Berner AM, Sposito T, Thirlwell C. The evolving (epi)genetic landscape of pancreatic neuroendocrine tumours. Endocr Relat Cancer. 2019;26(9):R519.PubMedCrossRef
47.
Cejas P, Drier Y, Dreijerink KMA, Brosens LAA, Deshpande V, Epstein CB, et al. Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors. Nat Med. 2019;25(8):1260–5.PubMedPubMedCentralCrossRef
48.••
. Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543(7643):65–71 This original article can be considered a hallmark in genomics of pancreatic neuroendocrine tumours and has generated significant knowledge on molecular subtypes.PubMedCrossRef
49.
Fernandez-Cuesta L, Peifer M, Lu X, Sun R, Ozretić L, Seidel D, et al. Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nat Commun. 2014;5(1):3518.PubMedCrossRef
50.•
. Alcala N, Leblay N, Gabriel AAG, Mangiante L, Hervas D, Giffon T, et al. Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids. Nat Commun. 2019;10(1):3407 In this work using multi-omics factor analyses, the authors identified clinically relevant subgroups of large cell neuroendocrine carcinoma and identified the group of supracarcinoids.PubMedPubMedCentralCrossRef
51.
Konukiewitz B, Jesinghaus M, Steiger K, Schlitter AM, Kasajima A, Sipos B, et al. Pancreatic neuroendocrine carcinomas reveal a closer relationship to ductal adenocarcinomas than to neuroendocrine tumors G3. Hum Pathol. 2018;77:70–9.PubMedCrossRef
52.
Sadanandam A, Wullschleger S, Lyssiotis CA, Grotzinger C, Barbi S, Bersani S, et al. A cross-species analysis in pancreatic neuroendocrine tumors reveals molecular subtypes with distinctive clinical, metastatic, developmental, and metabolic characteristics. Cancer Discov. 2015;5(12):1296–313.PubMedPubMedCentralCrossRef
53.
Mafficini A, Scarpa A. Genomic landscape of pancreatic neuroendocrine tumours: the International Cancer Genome Consortium. J Endocrinol. 2018;236(3):R161–r7.PubMedPubMedCentralCrossRef
54.
Young K, Lawlor RT, Ragulan C, Patil Y, Mafficini A, Bersani S, et al. Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours. Gut. 2020:gutjnl-2020-569 321016.
55.
56.
Derks JL, van Suylen RJ, Thunnissen E, den Bakker MA, Groen HJ, Smit EF, et al. Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter? Eur Respir J. 2017;49(6):1601838.PubMedPubMedCentralCrossRef
Metadata
Title
Update on Histological Reporting Changes in Neuroendocrine Neoplasms
Authors
Konstantin Bräutigam
Antonio Rodriguez-Calero
Corina Kim-Fuchs
Attila Kollár
Roman Trepp
Ilaria Marinoni
Aurel Perren
Publication date
01-06-2021
Publisher
Springer US
Published in
Current Oncology Reports / Issue 6/2021
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-021-01062-6

Other articles of this Issue 6/2021

Current Oncology Reports 6/2021 Go to the issue

Leukemia (A Aguayo, Section Editor)

Erythroleukemia: an Update

Interventional Oncology (DC Madoff, Section Editor)

Locally Advanced Pancreatic Cancer: Percutaneous Management Using Ablation, Brachytherapy, Intra-arterial Chemotherapy, and Intra-tumoral Immunotherapy

Breast Cancer (AS Zimmer, Section Editor)

Managing Common Estrogen Deprivation Side Effects in HR+ Breast Cancer: an Evidence-Based Review

Correction

Correction to: Psychosocial Interventions for Pain Management in Advanced Cancer Patients: a Systematic Review and Meta-analysis

Interventional Oncology (DC Madoff, Section Editor)

Role of Machine Learning and Artificial Intelligence in Interventional Oncology

Gynecologic Cancers (J Brown and RW Naumann, Section Editors)

Immunotherapy in Cervical Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits